DiaMedica Therapeutics (DMAC) Cash & Current Investments (2017 - 2026)

DiaMedica Therapeutics has reported Cash & Current Investments for 10 years, with the latest figure at $51.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 41.33% year-over-year to $51.3 million; the trailing twelve-month figure through Mar 2026 stood at $51.3 million (up 41.33% YoY), and the FY2025 full-year result was $59.9 million, up 35.66% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $51.3 million, down from $59.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $59.9 million in Q4 2025, with the low at $2.8 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $39.8 million across 5 years, with a median of $44.1 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 94.22% — and 2023, when it surged 1571.4%.
• DiaMedica Therapeutics' Cash & Current Investments stood at $33.5 million in 2022, then soared by 57.89% to $52.9 million in 2023, then retreated by 16.54% to $44.1 million in 2024, then soared by 35.66% to $59.9 million in 2025, then slipped by 14.29% to $51.3 million in 2026.
• The last three Cash & Current Investments figures came in at $51.3 million (Q1 2026), $59.9 million (Q4 2025), and $55.3 million (Q3 2025), per Business Quant data.